08 Dec 2025
13m
ASH 2025: Kura Oncology CEO Troy Wilson discusses the recent approval of the company's menin inhibitor (KOMZIFTI) in R/R NPM1 mutated AML, and highlights ASH data in the front line setting
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.